Aug 05, 2025 • Motley Fool
SOMEWHAT-BULLISH
Ardelyx Q2 Revenue Jumps 33%
Ardelyx ( NASDAQ:ARDX ) , a biopharmaceutical company focused on gastrointestinal and cardiorenal therapeutics, reported its second quarter 2025 earnings on August 4, 2025. The headline news was a major revenue beat, with $97.7 million GAAP revenue reported for Q2 2025 compared to the $81.08 ...
Aug 04, 2025 • Zacks Commentary
NEUTRAL
Ardelyx ( ARDX ) Reports Q2 Loss, Tops Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of +38.46% and +15.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 04, 2025 • GlobeNewswire
BULLISH
Ardelyx Announces Changes to the Executive Leadership Team
Edward Conner, M.D. appointed Chief Medical Officer and John Bishop, Ph.D. appointed Chief Technical Operations Officer ...
Jul 29, 2025 • Zacks Commentary
NEUTRAL
Karyopharm Therapeutics ( KPTI ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jul 28, 2025 • Zacks Commentary
NEUTRAL
Earnings Preview: Ardelyx ( ARDX ) Q2 Earnings Expected to Decline
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jun 10, 2025 • Benzinga
NEUTRAL
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ardelyx, Inc. - ARDX - Ardelyx ( NASDAQ:ARDX )
NEW YORK, June 10, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Ardelyx, Inc. ( "Ardelyx" or the "Company" ) ARDX. Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.